Johnson & Johnson JNJ announced positive topline results from the pivotal late-stage MDD3001 study, which evaluated its investigational oral drug seltorexant in patients with major depressive disorder...
Source LinkJohnson & Johnson JNJ announced positive topline results from the pivotal late-stage MDD3001 study, which evaluated its investigational oral drug seltorexant in patients with major depressive disorder...
Source Link
Comments